1. Home
  2. ACET vs IZEA Comparison

ACET vs IZEA Comparison

Compare ACET & IZEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • IZEA
  • Stock Information
  • Founded
  • ACET 1947
  • IZEA 2006
  • Country
  • ACET United States
  • IZEA United States
  • Employees
  • ACET N/A
  • IZEA N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • IZEA Advertising
  • Sector
  • ACET Health Care
  • IZEA Consumer Discretionary
  • Exchange
  • ACET Nasdaq
  • IZEA Nasdaq
  • Market Cap
  • ACET 69.9M
  • IZEA 69.1M
  • IPO Year
  • ACET N/A
  • IZEA N/A
  • Fundamental
  • Price
  • ACET $0.81
  • IZEA $3.95
  • Analyst Decision
  • ACET Buy
  • IZEA
  • Analyst Count
  • ACET 4
  • IZEA 0
  • Target Price
  • ACET $5.50
  • IZEA N/A
  • AVG Volume (30 Days)
  • ACET 1.7M
  • IZEA 87.3K
  • Earning Date
  • ACET 11-05-2025
  • IZEA 11-13-2025
  • Dividend Yield
  • ACET N/A
  • IZEA N/A
  • EPS Growth
  • ACET N/A
  • IZEA N/A
  • EPS
  • ACET N/A
  • IZEA N/A
  • Revenue
  • ACET N/A
  • IZEA $36,935,906.00
  • Revenue This Year
  • ACET N/A
  • IZEA $11.15
  • Revenue Next Year
  • ACET N/A
  • IZEA $17.64
  • P/E Ratio
  • ACET N/A
  • IZEA N/A
  • Revenue Growth
  • ACET N/A
  • IZEA 12.49
  • 52 Week Low
  • ACET $0.45
  • IZEA $1.68
  • 52 Week High
  • ACET $1.54
  • IZEA $4.39
  • Technical
  • Relative Strength Index (RSI)
  • ACET 49.83
  • IZEA 52.55
  • Support Level
  • ACET $0.79
  • IZEA $3.56
  • Resistance Level
  • ACET $1.03
  • IZEA $4.10
  • Average True Range (ATR)
  • ACET 0.06
  • IZEA 0.27
  • MACD
  • ACET 0.00
  • IZEA 0.02
  • Stochastic Oscillator
  • ACET 18.11
  • IZEA 54.05

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

Share on Social Networks: